NASDAQ:COGT
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. reported net income of −$328.9M in fiscal 2025. Free cash flow was −$266.0M, and the diluted share count rose 24.1%.Summary generated from Cogent Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−73.7%
Debt / equity0.35
Free cash flow−$266.0M
FCF marginn/a
Share count change+24.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −76 | −148 | −208 | −276 | −333 |
| Net income | −72 | −140 | −192 | −256 | −329 |
| Free cash flow | −60 | −126 | −156 | −208 | −266 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 8-KEntry into a material agreement
Sep 2, 2026 - 4Insider transaction report
Aug 31, 2026 - 8-KOther events
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026